B-cell Maturation Antigen (BCMA) Targeted Therapies Market
- 2026 年市場規模
- USD 6.62 Bn
- 2033 年預估規模
- USD 21.34 Bn
- 年複合成長率 CAGR
- 18.2%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Product Type (CAR-T cell, Bispecific Antibodies, and Antibody Drug Conjugates), By Indication (Acute Lymphoblastic Leukemia, and Multiple Myeloma), By Geography ( North America, Latin America, Europe, Middle East and Africa, Asia Pacific)
報告摘要
Recurrence of multiple myeloma has been a highly prevalent health condition, which requires novel and effective immunotherapeutic treatment. According to Leukemia Research by Elsevier, as of 2014, the incidence of multiple myeloma is estimated to be around 120,000 cases per year, with a global prevalence of over one million cases. B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen targeted therapy for the treatment of multiple myeloma. BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs). These advanced therapies are expected to improve the survival rate of multiple myeloma patients.
Market Dynamics
Increasing prevalence of multiple myeloma is expected to favor the B-cell maturation antigen (BCMA) targeted therapies market worldwide. According to the American Cancer Society, U.S., in 2016, the lifetime risk for multiple myeloma was around 1 in 143 people, with an estimated 30,280 adults (17,490 men and 12,790 women) diagnosed with multiple myeloma. The mortality rate of the disease was estimated to be 12,590 (6,660 men and 5,930 women) in 2016. Key players are actively involved in the development of immunotherapies targeting BCMA for the treatment of multiple myeloma, the demand for which is expected to increase, This in turn, is expected to boost development of novel treatments for relapsed or refractory myeloma. Furthermore, patients undergoing existing drug therapies are prone to the risk of relapse. Hence, B-cell maturation antigen targeted therapy, which primarily addresses this concern is expected to gain rapid traction.
Market Taxonomy
This report segments the global B-cell maturation antigen (BCMA) targeted therapies market on the basis on product type, indication, and regions. On the basis of product type, the market is segmented into antibody drug conjugates, CAR-T cells, bispecific antibodies. On the basis of indication, the market is segmented into acute lymphoblastic leukemia and multiple myeloma. For comprehensive understanding of market dynamics, the global B-cell Maturation Antigen (BCMA) targeted therapies market is analyzed across key geographical regions namely, North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.
Key Features of the Study
• This report provides in-depth analysis of the global B-cell maturation antigen (BCMA) targeted therapies market and provides pipeline analysis for the same
• It elucidates potential opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, impact analysis, key developments, and competitive landscape
• It profiles leading players in the global B-cell maturation antigen (BCMA) targeted therapies market based on the following parameters – company overview, financial performance, product pipeline, geographical presence, and key developments
• Key companies covered as a part of this study include Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future BCMA targeted therapies product launch, market expansion, and marketing tactics
• The global BCMA targeted therapies market report caters to various stakeholders in this industry including, investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the B-Cell maturation antigen (BCMA) targeted therapies market
Market Segmentation
• By Product Type (Revenue, USD Bn, 2021-2033)
o Antibody Drug Conjugates
o CAR- T cells
o Bispecific Antibodies
• By Indication (Revenue, USD Bn, 2021-2033)
o Acute Lymphoblastic Leukemia
o Multiple Myeloma
• By Region (Revenue, USD Bn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Celgene Corporation
o GlaxoSmithKline plc.
o Novartis AG
o Juno Therapeutics
o Gilead Sciences, Inc.
o Amgen Inc.
o Affimed N.V.
o Poseida Therapeutics, Inc.
o Autolus Ltd.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Product Type
Market Snapshot, By Indication
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Product Type, 2021 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Antibody Drug Conjugates
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o CAR- T cells
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Bispecific Antibodies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
5. Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Indication, 2021 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Acute Lymphoblastic Leukemia
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Multiple Myeloma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
6. Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Region, 2021 – 2033, (USD Bn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Celgene Corporation
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
GlaxoSmithKline plc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Novartis AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Juno Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Gilead Sciences, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Amgen Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Affimed N.V.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Poseida Therapeutics, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Autolus Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們